How Promising is CRISPR for Fragile X?

Peter Todd, MD, PhD, Assistant Professor in the Department of Neurology in the University of Michigan Medical School, was awarded a FRAXA Research Grant for gene reactivation with the use of CRISPR. In this interview he tells us about CRISPR in Fragile X research, how realistic is it that it could turn the Fragile X gene back on, and if it can really cure Fragile X.

Read More »

Niagara Falls went Teal for Fragile X Awareness

Niagara Falls glowed teal on July 22 for Fragile X Awareness Day! Huge thanks to the Illumination Board for this stunning show of support.

Read More »
Human Neurons

Retinoic Acid Signaling is Blocked by Fragile X Mutation

With a 2013-2014 FRAXA Research Grant, Principal Investigator Marius Wernig, PhD and FRAXA Fellow Samuele Marro, PhD at Stanford University found that the Fragile X mutation impairs homeostatic plasticity in human neurons, by blocking synaptic retinoic acid signaling. Retinoic acid is a metabolite of Vitamin A. The system they have developed could provide a powerful new cellular biomarker for screening many treatment approaches.

Read More »
Todd-Haenfler

Fragile X Research Impacted by a Small Group of Thoughtful, Committed Citizens

Congrats to FXAM! Their months of effort paid off with a $35K grant to support Dr. Todd’s groundbreaking Fragile X CRISPR research.

Read More »
ringing the bell at the NYSE

Ringing the Bell at the New York Stock Exchange for Fragile X Awareness

FRAXA and NFXF rang the NYSE opening bell to raise awareness for Fragile X—an incredible moment shared worldwide on CNBC!

Read More »
Drs. Ingolia, Wren Kim, at University of California at Berkeley

Activity-Dependent Translational Profiling in Fragile X Neurons

FRAXA funded new tools at UC Berkeley to track which proteins Fragile X neurons make during signaling, to find targets that improve learning and brain function.

Read More »
Tetra Discovery Partners

Tetra Discovery Partners Initiates Phase 2 Trial of BPN14770 in Fragile X Syndrome

This 2-Period Crossover Study of BPN14770 is accepting adults males with Fragile X syndrome at Rush University Medical Center in Chicago. Principal Investigator of the study is Elizabeth Berry-Kravis, MD, PhD.
A selective inhibitor of the phosphodiesterase type-4D (PDE4D), BPN14770 has shown the ability to improve the quality of connections between neurons and to improve multiple behavioral outcomes in the Fragile X mouse model.

Read More »
Devon Binder, PhD; Iryna Ethell, PhD, Patricia Pirbhoy, PhD, at UC Riverside School of Medicine

Understanding and Reversing Hypersensitivity to Sounds in Fragile X Syndrome

This FRAXA grant studied why people with Fragile X are overly sensitive to sound and tested drug strategies to calm the brain’s overactive auditory circuits.

Read More »

Meet Drew!

Meet #FriendofFRAXA Drew! If you would like to nominate someone as a #FriendofFRAXA, we welcome all who have been touched by Fragile X, including friends, grandparents, siblings, professionals and companions alike to become a #FriendofFRAXA with the goal of putting a face to Fragile X for those who may not know someone directly.

Read More »
Peng Jin Team at Emory University

Three-Dimensional Model for Identifying Fragile X Treatments

With a $90K FRAXA grant, Emory scientists are creating Fragile X brain organoids—3D human cell models—to reveal disease mechanisms and guide new treatments.

Read More »
Patrick McCamphill

Pharmacological Tolerance in the Treatment of Fragile X Syndrome

FRAXA funded MIT work to probe tolerance to key Fragile X drugs, including mGluR5 inhibitors and arbaclofen, and to identify ways to sustain long-term treatment benefits.

Read More »

Lysogene Partners with FRAXA Investigator Dr. Hervé Moine to Develop Gene Therapy for Fragile X

A research project funded by FRAXA has led to new fragile x gene therapy initiative, this time in France. Lysogene, a French biopharmaceutical company working to develop gene therapy treatments for brain disorders, is partnering with FRAXA Investigator Dr. Herve Moine to tackle Fragile X syndrome.

Read More »
Fragile X Conference

FRAXA Funded Researchers Present at MA Fragile X Conference

Boston Children’s Hospital hosted a Fragile X conference with FRAXA-funded researchers Dr. Craig Erickson & Dr. Carol Wilkinson presenting.

Read More »

Meet Zack!

Meet #FriendofFRAXA Zack! If you would like to nominate someone as a #FriendofFRAXA, we welcome all who have been touched by Fragile X, including friends, grandparents, siblings, professionals and companions alike to become a #FriendofFRAXA with the goal of putting a face to Fragile X for those who may not know someone directly.

Read More »
Noah FriendofFRAXA

Meet Noah!

Meet #FriendofFRAXA Noah! If you would like to nominate someone as a #FriendofFRAXA, we welcome all who have been touched by Fragile X, including friends, grandparents, siblings, professionals and companions alike to become a #FriendofFRAXA with the goal of putting a face to Fragile X for those who may not know someone directly.

Read More »

Meet Theo!

Meet #FriendofFRAXA Theo! If you would like to nominate someone as a #FriendofFRAXA, we welcome all who have been touched by Fragile X, including friends, grandparents, siblings, professionals and companions alike to become a #FriendofFRAXA with the goal of putting a face to Fragile X for those who may not know someone directly.

Read More »
Healx team 2018

Repurposing Study II: Evaluating Combinations of Drugs to Treat Fragile X

FRAXA partnered with Healx to use AI to find approved drugs and drug combos that could treat Fragile X. Top candidates are now being tested in Fragile X models.

Read More »

Meet Giovanni!

Meet #FriendofFRAXA Giovanni! If you would like to nominate someone as a #FriendofFRAXA, we welcome all who have been touched by Fragile X, including friends, grandparents, siblings, professionals and companions alike to become a #FriendofFRAXA with the goal of putting a face to Fragile X for those who may not know someone directly.

Read More »
Craig Erickson, MD, Cincinnati Children's Hospital

Fragile X Clinical Trial of AZD7325 in Adults

FRAXA funded a trial of AZD7325, a drug that boosts GABA(A), in adults with Fragile X. Led by Dr. Craig Erickson, it also tested innovative biomarkers for future trials.

Read More »
Adam #FriendofFRAXA

Meet Adam!

Meet #FriendofFRAXA Adam! If you would like to nominate someone as a #FriendofFRAXA, we welcome all who have been touched by Fragile X, including friends, grandparents, siblings, professionals and companions alike to become a #FriendofFRAXA with the goal of putting a face to Fragile X for those who may not know someone directly.

Read More »
gratitude Fragile X research

FRAXA Annual Appeal Raised $760,000

Together we raised $760K and earned a $600K match from the Sunshine Lady Foundation, fueling hope for Fragile X treatments and a cure!

Read More »

Meet Graham!

Meet #FriendofFRAXA Graham! If you would like to nominate someone as a #FriendofFRAXA, we welcome all who have been touched by Fragile X, including friends, grandparents, siblings, professionals and companions alike to become a #FriendofFRAXA with the goal of putting a face to Fragile X for those who may not know someone directly.

Read More »
bruins total

$17,469 Raised by Friends of FRAXA Volunteers at Bruins Game

Over 50 #FriendsofFRAXA volunteers sold $34,938 in 50/50 raffle tickets at the Bruins game—raising $17,469 for Fragile X research!

Read More »

Meet Makenzie!

Meet #FriendofFRAXA Makenzie! If you would like to nominate someone as a #FriendofFRAXA, we welcome all who have been touched by Fragile X, including friends, grandparents, siblings, professionals and companions alike to become a #FriendofFRAXA with the goal of putting a face to Fragile X for those who may not know someone directly.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (38)